The relationship between erectile dysfunction (ED) and hypertension is a focus in andrological research. ED and hypertension share some pathophysiologic pathways, such as oxidative stress-induced endothelial dysfunction and up-regulated RhoA/Rho kinase activity, and both are the diseases at different stages of the pathological process of vascular dysfunction. Thus, it is particularly important to conduct regular and meticulous evaluation of such patients, so as to give rational individualized medication. Phosphodiesterase-5 inhibitors have an excellent efficacy and safety profile in the management of hypertension, either used alone or with antihypertensive medication. At present, gene therapy and adipose-derived stem cell therapy have displayed favorable prospects in the management of ED and hypertension, and translational medicine may help bring more clinical benefits.